Primary source: US Food and Drug Administration (FDA)
FDA published final guidance on certain postapproval requirements for ANDA holders, reiterating obligations for post-approval supplements, annual reports, and post-marketing safety reporting under 21 CFR 314.80.
This guidance impacts all ANDA holders by clarifying FDA expectations for safety reporting and maintenance, ensuring compliance with post-marketing pharmacovigilance requirements.
Review the guidance to ensure compliance with post-marketing safety reporting timelines and annual report submissions; update SOPs for ICSR processing and periodic report generation.
Regulatory Intelligence Lead
quarterly
The guidance clarifies procedures for post-approval supplements (21 CFR 314.70), annual reports (21 CFR 314.81), and post-marketing safety reporting obligations (21 CFR 314.80). It serves as a centralized resource for generic drug manufacturers to ensure they meet maintenance requirements after approval.
Reinforces post-marketing safety reporting requirements for ANDA holders, ensuring consistent submission of safety data and periodic reports to the FDA.
Review the guidance to ensure compliance with post-marketing safety reporting timelines and annual report submissions; update SOPs for ICSR processing and periodic report generation.
The guidance reinforces post-marketing safety reporting obligations for ANDA holders, including consistent submission of safety data and periodic reports to FDA.
What changed: FDA published final guidance on certain postapproval requirements for ANDA holders, reiterating obligations for post-approval supplements, annual reports, and post-marketing safety reporting under 21 CFR 314.80.
Why it matters: This guidance impacts all ANDA holders by clarifying FDA expectations for safety reporting and maintenance, ensuring compliance with post-marketing pharmacovigilance requirements.
Practical implication: Review the guidance to ensure compliance with post-marketing safety reporting timelines and annual report submissions; update SOPs for ICSR processing and periodic report generation.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
